A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone

L. Dziggel, B. Segedin, N. H. Podvrsnik, I. Oblak, S. E. Schild, D. Rades

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and purpose: This study aimed to develop and validate a scoring system to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases from less radiosensitive tumors. Patients and methods: The study included data from 176 patients with brain metastasis from renal cell carcinoma, malignant melanoma or colorectal cancer. Patients were divided into a test group (N = 88) and a validation group (N = 88). In the multivariate analysis of the test group, age, Karnofsky Performance Status and extracranial metastasis were significantly associated with survival. These three factors were included in the scoring system. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the three scores. According to the total scores - which ranged from 5 to 14 points - three prognostic groups were created. Results: The 6-month survival rates in the test group were 11 % for 5-8 points (N = 47, group A), 38 % for 9-11 points (N = 29, group B) and 83 % for 12-14 points (N = 12, group C). In the validation group the 6-month survival rates were 12, 31 and 75 %, respectively. Comparisons between the prognostic groups A, B and C of the test group with those of the validation group did not reveal any significant differences. Conclusion: The new scoring system based on three independent prognostic factors can help to estimate the survival of patients with brain metastases from a less radiosensitive tumor. The score appears to be valid and reproducible.

Original languageEnglish (US)
Pages (from-to)54-58
Number of pages5
JournalStrahlentherapie und Onkologie
Volume190
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Radiotherapy
Neoplasm Metastasis
Survival
Brain
Survival Rate
Neoplasms
Karnofsky Performance Status
Renal Cell Carcinoma
Colorectal Neoplasms
Melanoma
Multivariate Analysis
Age Groups

Keywords

  • Karnofsky Performance Status
  • Metastasis
  • Radiosensitivity
  • Score
  • Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone. / Dziggel, L.; Segedin, B.; Podvrsnik, N. H.; Oblak, I.; Schild, S. E.; Rades, D.

In: Strahlentherapie und Onkologie, Vol. 190, No. 1, 01.2014, p. 54-58.

Research output: Contribution to journalArticle

Dziggel, L. ; Segedin, B. ; Podvrsnik, N. H. ; Oblak, I. ; Schild, S. E. ; Rades, D. / A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone. In: Strahlentherapie und Onkologie. 2014 ; Vol. 190, No. 1. pp. 54-58.
@article{8e903a4db1dc4358a084377892020b30,
title = "A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone",
abstract = "Background and purpose: This study aimed to develop and validate a scoring system to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases from less radiosensitive tumors. Patients and methods: The study included data from 176 patients with brain metastasis from renal cell carcinoma, malignant melanoma or colorectal cancer. Patients were divided into a test group (N = 88) and a validation group (N = 88). In the multivariate analysis of the test group, age, Karnofsky Performance Status and extracranial metastasis were significantly associated with survival. These three factors were included in the scoring system. The score for each factor was determined by dividing the 6-month survival rate (in {\%}) by 10. The total score represented the sum of the three scores. According to the total scores - which ranged from 5 to 14 points - three prognostic groups were created. Results: The 6-month survival rates in the test group were 11 {\%} for 5-8 points (N = 47, group A), 38 {\%} for 9-11 points (N = 29, group B) and 83 {\%} for 12-14 points (N = 12, group C). In the validation group the 6-month survival rates were 12, 31 and 75 {\%}, respectively. Comparisons between the prognostic groups A, B and C of the test group with those of the validation group did not reveal any significant differences. Conclusion: The new scoring system based on three independent prognostic factors can help to estimate the survival of patients with brain metastases from a less radiosensitive tumor. The score appears to be valid and reproducible.",
keywords = "Karnofsky Performance Status, Metastasis, Radiosensitivity, Score, Survival",
author = "L. Dziggel and B. Segedin and Podvrsnik, {N. H.} and I. Oblak and Schild, {S. E.} and D. Rades",
year = "2014",
month = "1",
doi = "10.1007/s00066-013-0394-2",
language = "English (US)",
volume = "190",
pages = "54--58",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "1",

}

TY - JOUR

T1 - A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone

AU - Dziggel, L.

AU - Segedin, B.

AU - Podvrsnik, N. H.

AU - Oblak, I.

AU - Schild, S. E.

AU - Rades, D.

PY - 2014/1

Y1 - 2014/1

N2 - Background and purpose: This study aimed to develop and validate a scoring system to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases from less radiosensitive tumors. Patients and methods: The study included data from 176 patients with brain metastasis from renal cell carcinoma, malignant melanoma or colorectal cancer. Patients were divided into a test group (N = 88) and a validation group (N = 88). In the multivariate analysis of the test group, age, Karnofsky Performance Status and extracranial metastasis were significantly associated with survival. These three factors were included in the scoring system. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the three scores. According to the total scores - which ranged from 5 to 14 points - three prognostic groups were created. Results: The 6-month survival rates in the test group were 11 % for 5-8 points (N = 47, group A), 38 % for 9-11 points (N = 29, group B) and 83 % for 12-14 points (N = 12, group C). In the validation group the 6-month survival rates were 12, 31 and 75 %, respectively. Comparisons between the prognostic groups A, B and C of the test group with those of the validation group did not reveal any significant differences. Conclusion: The new scoring system based on three independent prognostic factors can help to estimate the survival of patients with brain metastases from a less radiosensitive tumor. The score appears to be valid and reproducible.

AB - Background and purpose: This study aimed to develop and validate a scoring system to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases from less radiosensitive tumors. Patients and methods: The study included data from 176 patients with brain metastasis from renal cell carcinoma, malignant melanoma or colorectal cancer. Patients were divided into a test group (N = 88) and a validation group (N = 88). In the multivariate analysis of the test group, age, Karnofsky Performance Status and extracranial metastasis were significantly associated with survival. These three factors were included in the scoring system. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the three scores. According to the total scores - which ranged from 5 to 14 points - three prognostic groups were created. Results: The 6-month survival rates in the test group were 11 % for 5-8 points (N = 47, group A), 38 % for 9-11 points (N = 29, group B) and 83 % for 12-14 points (N = 12, group C). In the validation group the 6-month survival rates were 12, 31 and 75 %, respectively. Comparisons between the prognostic groups A, B and C of the test group with those of the validation group did not reveal any significant differences. Conclusion: The new scoring system based on three independent prognostic factors can help to estimate the survival of patients with brain metastases from a less radiosensitive tumor. The score appears to be valid and reproducible.

KW - Karnofsky Performance Status

KW - Metastasis

KW - Radiosensitivity

KW - Score

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84891528142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891528142&partnerID=8YFLogxK

U2 - 10.1007/s00066-013-0394-2

DO - 10.1007/s00066-013-0394-2

M3 - Article

C2 - 23861153

AN - SCOPUS:84891528142

VL - 190

SP - 54

EP - 58

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 1

ER -